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0929-6646/Copyright ª 2014, ElsevierBackground/Purpose: Alcohol use may have negative impacts on hepatitis C virus (HCV) treat-
ment due to low adherence, and racial differences can influence HCV sustained virological
response (SVR) rate between East Asian and European ancestry. The objective of this study
is to confirm the influence of alcohol consumption and racial differences on HCV treatment
outcome in aboriginal and nonaboriginal people of southeastern Taiwan.
Methods: In this retrospective cohort study, a total of 195 patients were treated with
peginterferon-alpha once weekly plus ribavirin for 24 weeks. The efficacy analysis was per-
formed based on the SVR rate for patients who received at least one dose of the study medi-
cation or who completed treatment. The endpoints were denoted by virological response rate
including the influences of alcohol use, HCV genotype, serum level of HCV virological load, and
racial differences.
Results: No differences were observed in the baseline clinical characteristics between drinkers
and nondrinkers, but a significant difference was noted in the body mass index betweeneclare that they have no competing interests.
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1070 C.-C. Lin et al.aboriginal and nonaboriginal populations (28.3 vs. 25.8; p < 0.01). With respect to the SVR
rate, no difference was found between drinkers and nondrinkers, and between aboriginal
and nonaboriginal people. The treatment efficacy of SVR in the whole group was significantly
different between patients with HCV genotype 1 and nongenotype 1 (73.5% vs. 91.2%;
p < 0.01). An analysis of the SVR rate in the aboriginal group showed no significant difference
between patients with genotype 1 and nongenotype 1 (80.0% vs. 91.3%; p Z 0.31).
Conclusion: In southeastern Taiwan, alcohol consumption did not influence the HCV treatment
outcome, and the SVR rates were similar between patients with HCV genotype 1 and nongeno-
type 1 infections in the aboriginal group.
Copyright ª 2014, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Alcoholic hepatitis and viral hepatitis represent the most
popular liver diseases in the world, and the prevalence of
hepatitis C virus (HCV) infection is from three- to 30-fold
higher in alcoholic individuals compared with the general
population.1 Previous literatures have demonstrated a
synergistic effect of hazardous or heavy alcohol consump-
tion and HCV infection on the progression of liver disease to
cirrhosis and the development of hepatocellular
carcinoma.2,3
Taitung is a multiracial county in southeastern Taiwan;
although Lin et al4 reported that chronic HCV infections and
alcohol drinking play important roles in the development of
chronic liver disease in Taiwanese aborigines, the treat-
ment efficacy in this endemic area is still unclear. Although
Ohnishi et al5 reported that a history of excessive alcohol
consumption was associated with a lower rate of HCV
eradication in patients receiving 6e10 MU of interferon
(IFN)-based regimen, Bruggmann et al6 stated that sus-
tained virological response (SVR) rates of drinkers with a
daily amount of alcohol intake of up to 24 g during hepatitis
C pegylated IFN-based therapy were comparable to that of
nondrinkers.
Race is an important factor to influence chronic HCV
infection treatment outcome. In Taiwan, the naı¨ve patients
with HCV genotype 1 treated with pegylated IFN-alpha plus
ribavirin for 24 weeks or 48 weeks have a higher SVR rate
than those in the West,7 but the influence on aboriginal and
nonaboriginal groups is unclear.
In this retrospective cohort study, we evaluated the
effect of hazardous alcohol consumption and race differ-
ence on treatment response to 24 weeks of peg-IFN plus
ribavirin treatment in naı¨ve patients with chronic hepatitis
C infection. The aim was to investigate the difference in
the SVR rate between drinker and nondrinker groups, and
to evaluate the possible influences of race on virological
response.Methods
Patients and study procedure
In this retrospective cohort study, we recruited patients
with chronic hepatitis C from hepatology clinics of
Mackay Memorial Hospital, Taitung branch, Taitung,Taiwan who were treated according to the Taiwan Na-
tional Health Insurance clinical practice guidelines
[seropositive for HCV antibodies and HCV RNA, and serum
alanine transaminase (ALT) above 40 IU/L] from January
2010 to January 2013. Inclusion criteria were patients
aged 20 years or older and naı¨ve patients with chronic
hepatitis C infection who were treated with peg-IFN-
alpha and ribavirin. The naı¨ve HCV patients recruited in
this study were divided into aboriginal and nonaboriginal
groups, which were then subdivided into drinker and
nondrinker groups. HCV genotype was divided into ge-
notype 1 and nongenotype 1. Baseline serum HCV viral
load was divided into high viral load (>4  105 IU/mL) and
low viral load (4  105 IU/mL). The treatment course
was peg-IFN-alpha-2a (180 mg/week) or peg-IFN-alpha-2b
(1.5 mg/kg/week) plus weight-based ribavirin (800 mg for
weight <65 kg; 1000 mg for weight 65e80 kg; and
1200 mg for weight >80 kg) for 24 weeks, and the dose of
peg-IFN and ribavirin was modified according to the pre-
scribing information. This analysis relates to the defini-
tion of hazardous alcohol use; the definition of a drinker
was according to the hazardous alcohol consumption
volume which is defined as an average rate of consump-
tion of >20 g and >40 g of pure alcohol daily for women
and men, respectively.8
Biochemical analysis
At the beginning of the treatment, patients attended one
session of therapeutic education with a reference nurse,
during which they were taught the practice of treatment
and management of side effects; they had biweekly
outpatient visits during the 1st month and then monthly
visits during the rest of the treatment and follow-up pe-
riods. Information on clinical sociodemographic factors,
including age, sex, race, weight, and body mass index
(BMI), and a medical history of accompanying diseases and
treatment side effects were collected. Blood biochemistry
were performed to evaluate serum anti-HCV, serum HCV
RNA levels, hepatitis B virus surface antigen, white blood
cell count, hemoglobin, platelet count, aspartate amino-
transferase (AST), and ALT levels. Abdominal ultrasound
was also performed in all patients every 6 months to detect
liver tumor and cirrhosis. HCV RNA was measured by a
Roche Amplicor polymerase chain reaction (PCR) assay, and
the lower limit of detection and quantitation was 15 IU/mL.
HCV genotyping was performed by primer-specific PCR and
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Figure 1 Flow diagram showing the classification of all naı¨ve
hepatitis C patients treated with peginterferon alpha and
ribavirin into different groups. It also indicates the number of
patients in the aboriginal and nonaboriginal groups.
HCV Z hepatitis C virus.
Impact of alcohol and race on HCV treatment 1071further confirmed by direct PCR deep-sequencing using an
ABI 3730 sequencer.
Efficacy analysis
A rapid virological response was defined as a failure to
detect HCV RNA at Week 4 of treatment by a sensitive PCR-
based quantitative analysis. An early virological response
was defined as an undetectable HCV RNA level or at least 2-
log 10 decrease from the baseline level of serum HCV RNA
at Week 12 of treatment. An end-of-treatment virological
response was defined as an undetectable HCV RNA level at
the end of Week 24 of treatment. The SVR was defined as
serum HCV RNA being undetectable through 24 weeks after
cessation of treatment. The analysis of SVR was according
to patients who received at least one dose of therapy, and
all missing SVR results were coded as failures. In the best
scenario, the SVR was evaluated in the population that
completed treatment; the definition of treatment
completion rate is the percentage of population who had
available data to assess SVR. The endpoints were by viro-
logical response rate including the influences of alcohol
use, HCV genotype, serum level of HCV virological load, and
the racial differences.
Statistical analysis
All patients who received at least one dose of medication
were included in all efficacy analyses. The data of cate-
gorical variables were compared using a Chi-square test
including odds ratios and respective 95% confidence in-
tervals for the association of SVR with each category of
patient’s characteristics; continuous variables were
compared by Student t test. Statistical analyses were per-
formed using the SPSS 12.0 statistical package (SPSS Inc.,
Chicago, IL, USA). Missing data were treated using the SPSS
missing value options. All statistical analyses were based on
two-sided hypothesis tests with a significance level of
p < 0.05.
Results
A total of 195 naı¨ve, adult chronic hepatitis C patients who
were treated with peg-IFN-alpha plus ribavirin were
included in this study; they were divided into aboriginal
(n Z 49) and nonaboriginal (n Z 146) groups, and then
further subdivided into drinker and nondrinker groups
(Figure 1). The treatment completion rate was 77.6% (38/
49) in the aboriginal group and 82.9% (121/146) in the
nonaboriginal group. The average completed treatment
rate in this study was 81.5%.
Demographic and clinical characteristics of naı¨ve HCV
patients in the aboriginal (n Z 49) and nonaboriginal
(n Z 146) (121/146) were similar with respect to sex pro-
portion, mean age, baseline hemoglobin, baseline white
blood cell (WBC), baseline platelet count, and baseline HCV
viral load. The mean BMI in the aboriginal group was
significantly higher than that in the nonaboriginal group
(28.3  4.2 vs. 25.8  4.3; p < 0.01), but no significant
difference was observed in baseline ALT, AST, and liver
cirrhosis percentage between these two groups (Table 1).Comparison of the demographic and clinical characteristics
of these patients between the drinker (n Z 114) and
nondrinker (n Z 81) groups showed no differences in sex
proportion, mean age, mean body weight, BMI, baseline
hemoglobin, baseline WBC, baseline platelet count, base-
line HCV viral load, baseline ALT, AST, and liver cirrhosis
percentage (Table 2).
The SVR rate, for patients who received at least one
dose of the study medication, was 65.5% in the aboriginal
drinker group, 69.4% in the nonaboriginal drinker group,
70.0% in the aboriginal nondrinker group , and 65.6% in the
nonaboriginal nondrinker group; no significant difference
was observed between these four groups (Table 3). The
odds ratios according to patient’s characters, there was
significant difference in genotype 1 (p Z 0.01, Table 4).
However, in the best scenario, among patients who
completed treatment, the SVR rate was 82.6% (19/23) in
the aboriginal drinker group, 83.1% (59/71) in the non-
aboriginal drinker group, 93.3% (14/15) in the aboriginal
nondrinker group, and 82.0% (41/50) in the nonaboriginal
nondrinker group.
In this study, with respect to the completed treatment
SVR rate, no significant difference was observed between
the aboriginal and nonaboriginal groups (Figure 2A). The
completed treatment SVR rate in the low viral load group
(90.2%) was higher than that in the high viral load group
(80.6%), but there were still no significant differences
(p Z 0.13). If we divided all patients into groups of those
with HCV genotype 1 and nongenotype 1, a significant dif-
ference was observed in the completed treatment SVR rate
between these groups (73.5% vs. 91.2%; p < 0.01). Inter-
estingly, if we considered only aboriginal patients, no sig-
nificant differences were observed in the completed
treatment SVR rate between patients with HCV genotype 1
and nongenotype 1 (Figure 2B; p Z 0.31).
Discussion
Overweight and obesity, which may lead to type II diabetes,
metabolic syndrome, coronary heart disease, chronic liver
disease, and so on, have been recognized as major public
health concerns. In Taiwan, overweight and obesity are
more prevalent among the aborigines, but the causal rea-
sons revealed a poor association between these and alcohol
drinking or physical activity.9 Wang et al10 have
Table 1 Demographic and clinical characters of naı¨ve HCV patients according to race.
Aboriginal (n Z 49) Nonaboriginal (n Z 146) p
Patient related
Male 23 (46.9) 74 (50.7) 0.65
Age 57.4  8.6 54.7  10.8 0.07
Weight (kg) 71.8  12.7 66.4  13.4 0.02
BMI 28.3  4.2 25.8  4.3 <0.01
Baseline ALT (IU/L) 129.6  94.7 118.5  82.3 0.45
Baseline AST (IU/L) 92.7  59.1 93.8  70.9 0.92
Baseline Hb (g/dL) 13.7  1.8 13.9  1.5 0.50
Baseline WBC (mL) 5641  1862 5075  1879 0.08
Baseline PLT (103/mL) 165  65 157  76 0.53
Liver cirrhosis 10 (20.4) 23 (15.8) 0.45
HCV disease related
Genotype 1 20 (40.8) 65 (44.5) 0.65
Baseline HCV viral load > 4 105 IU/mL 30 (61.2) 103 (70.5) 0.23
HCV therapy related
Pegylated interferon alpha 2a/2b (n/n) 8/41 25/121 0.90
Data are presented as n (%) or mean  SD.
ALT Z alanine transaminase; AST Z aspartate aminotransferase; BMI Z body mass index; Hb Z hemoglobin; HCV Z hepatitis C virus;
PLT Z platelet; SD Z standard deviation, WBC Z white blood cell.
1072 C.-C. Lin et al.demonstrated that the G-2548A polymorphism of the leptin
gene is correlated with extreme obesity in Taiwanese ab-
origines. Genetic factors may explain why Taiwanese ab-
origines have a high BMI (28.3); in this study, we found that
the odds ratio in those with a body weight of >80 kg was
1.54 (p Z 0.26).
Regarding the chronic HCV treatment outcomes of
drinkers, the nonpegylated IFN therapy for chronic HCV was
less effective in heavy drinkers (>70 g/day of ethanol
intake) than in nondrinkers.11 The synergy between alcoholTable 2 Demographic and clinical characters of naı¨ve HCV pat
Drinker (n
Patient related
Aboriginal 29 (25.4)
Male 61 (53.5)
Age 54.8  10.
Weight (kg) 68.3  12.
BMI 26.6  4.5
Baseline ALT (IU/L) 122.8  88
Baseline AST (IU/L) 91.8  59.
Baseline Hb (g/dL) 13.9  1.5
Baseline WBC (mL) 5298  193
Baseline PLT (103/mL) 163  63
Liver cirrhosis 21 (18.4)
HCV disease related
Genotype 1 52 (45.6)
Baseline HCV viral load > 4 105 IU/mL 77 (67.5)
HCV therapy related
Pegylated interferon alpha 2a/2b (n/n) 17/97
Data are presented as n (%) or mean  SD.
ALT Z alanine transaminase; AST Z aspartate aminotransferase; BMI
PLT Z platelet; SD Z standard deviation, WBC Z white blood cell.and HCV might be due to increased oxidative stress, and the
lower response rates to IFN therapy in alcoholics with HCV
infection are likely due to noncompliance.1 In one recent
study, a multidisciplinary approach to treating hepatitis C
with pegylated IFN and ribavirin in alcohol-dependent pa-
tients with ongoing abuse showed a similar SVR in patients
and controls (48% vs. 49%).12 In our study, we employed a
reference nurse to make regular visits to help patients and
found that the SVR rate of the drinker group (68.4%) was
similar to that of the nondrinker group (66.6%). However,ients according to alcohol intake.
Z 114) Nondrinker (n Z 81) p
20 (24.7) 0.91
36 (44.4) 0.21
9 56.2  9.6 0.33
6 66.9  14.5 0.47
26.2  4.3 0.53
.6 119.5  81.7 0.80
2 96.0  79.1 0.70
13.8  1.6 0.67
0 5118  1823 0.54
154  87 0.44
12 (14.8) 0.51
33 (40.7) 0.50
56 (69.1) 0.81
16/65 0.37
Z body mass index; Hb Z hemoglobin; HCV Z hepatitis C virus;
Table 3 Sustained virological response rate according to patients who received at least one dose of the study medication.
Aboriginal drinker
(n Z 29)
Nonaboriginal drinker
(nZ 85)
Aboriginal nondrinker
(n Z 20)
Nonaboriginal nondrinker
(n Z 61)
p
22 (75.9) 73 (85.9) 16 (80.0) 49 (80.3)
cEVR 25 (86.2) 76 (89.4) 18 (90.0) 54 (88.5)
pEVR 0 2 (2.4) 0 0
EOTVR 25 (86.2) 76 (89.4) 17 (85.0) 50 (82.0)
SVR 19 (65.5) 59 (69.4) 14 (70.0) 40 (65.6) 0.84
Data are presented as n (%).
cEVRZ complete early virological response; EOTVRZ end of treatment virological response; pEVRZ partial early virological response;
RVR Z rapid virological response; SVR Z sustained virological response.
Impact of alcohol and race on HCV treatment 1073hazardous drinking is a pattern of alcohol consumption that
increases the risk of harmful consequences for the user and
others.
Adherence to IFN and ribavirin treatment is very useful in
patients with chronic hepatitis C who consume alcohol.
Anand et al13 reported that recent alcohol use (within the
past 12 months) was associated with increased treatment
discontinuation (40% vs. 26%) and lower SVR (14% vs. 20%);
however, patients who use alcohol and completed the
treatment showed a response rate comparable to that of
nondrinkers (25% vs. 23%). In the best scenario of this study,
among patients who completed treatment, the completed
treatment SVR rate of the drinker group (83.0%) was similar
to that of the nondrinker group (84.6%). The higher SVR rate
in our study than that observed in previous literature may be
due to the higher adherence to the pegylated IFN therapy.
HCV genotype, serum viral load, treatment duration,
rapid virus response, and race difference have been shown
to be prognostic indicators of therapy outcome. In Taiwan,
both 24 weeks and 48 weeks of dual therapy can achieve a
high SVR rate in patients having HCV genotype 1 with low
viral load and rapid virological response.14 Recently, Ge
et al15 reported a strong association between the
interleukin-28B (IL28B) gene encoding IFN-l-3 and the
treatment outcomes of peg-IFN-alpha plus ribavirin ther-
apy. These varieties in the IL28B gene correlated with HCV
viral clearance and SVR, which may explain the different
SVR rates among African-Americans, Europeans, and Asians.Table 4 Sustained virological response rate and odds ratio acco
medication.
Characteristics Frequency o
with SVR
Male 97 (69.0)
Age > 55 y 107 (68.2)
BW > 80 kg 35 (60)
Drinker 114 (68.4)
Aboriginal 49 (67.3)
Genotype 1 85 (58.8)
Baseline HCV viral load > 4 105 IU/mL 133 (65.4)
Liver cirrhosis 33 (54.5)
Data are presented as n (%).
CI Z confidence interval; HCV Z hepatitis C virus; n (%) Z patient
virological response.Asian patients had the highest frequency of the advanta-
geous allele in the IL28B gene, with up to 88% of Taiwanese
patients with chronic hepatitis C having the rs8099917 TT
genotype, which has been shown to be an important pre-
dictor of response.16 In southern Taiwan, Huang et al17
demonstrated that the host genetic variants of rs8099917
were associated with HCV characteristics, which showed
that the TT genotype was over-represented among HCV
nongenotype 1-infected patients compared to HCV geno-
type 1-infected patients (91.4% vs. 85.0%). In our study, we
demonstrated that the treatment outcome of HCV geno-
type 1 was inferior to that of nongenotype 1, but the in-
fluence might be decreased in southeastern Taiwanese
aboriginals, and its mechanism was worth further
investigation.
Additional important issues associated IFN-based
therapy outcome of HCV genotype 1 were HCV muta-
tions including NS5A mutation and core region sub-
stitutions, but controversy still exists. In a previous study,
Hung et al18 stated that Taiwanese patients with an NS5A
mutant type had a higher rate of SVR (67%) of combination
therapy than those with wild type (23%); by contrast, Yang
et al19 reported that NS5A heterogeneity is not a reliable
predictor of responsiveness to IFN plus ribavirin combi-
nation therapy in Taiwanese HCV genotype 1b patients.
With respect to HCV core gene polymorphisms, Liang
et al20 reported that pretreatment screening of amino
acid substitutions in the core region could help identifyrding to patients who received at least one dose of the study
f patients Univariate analysis
OR (95% CI) p
0.92 (0.51e1.69) 0.80
1.00 (0.55e1.83) > 0.99
1.54 (0.72e3.28) 0.26
0.98 (0.53e1.80) 0.94
1.05 (0.53e2.11) 0.88
2.15 (1.17e3.97) 0.01
1.52 (0.78e2.98) 0.22
2.04 (0.95e4.38) 0.06
number and SVR percentage; OR Z odds ratio; SVR Z sustained
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Figure 2 (A) Completed treatment SVR rate of patients with
genotype 1 was inferior to that of patients with nongenotype 1.
(B) No difference was observed in the completed treatment SVR
rate in patients with genotype 1 between aboriginal and non-
aboriginal groups. AZ aboriginal; completed sustained virolog-
ical response rate Z sustained virological response rate in the
population that completed treatment; G1 Z genotype 1;
HVLZ high viral load; LVL Z low viral load (400,000 IU/mL);
non-AZnonaboriginal;non-G1Znongenotype1;SVRZ sustained
virological response.
1074 C.-C. Lin et al.patients who are good candidates for peg-IFN plus riba-
virin therapy; by contrast, Hsu et al21 stated that HCV
core gene polymorphisms correlate with liver fibrosis but
not with SVR in Taiwanese patients with genotype 1
infection.
Certain alleles of alcohol dehydrogenase (ADH) and
aldehyde dehydrogenase (ALDH) gene variants have been
shown to influence a person’s drinking levels and the risk of
developing alcohol abuse or dependence. Chen et al22 re-
ported that the odds ratios for an increment of one allele of
ADH2*1, ADH3*2, and ALDH2*1 in the development of
alcoholism in Taiwanese Han were 4.18, 3.82, and 6.89,
respectively; Peng et al23 also found that ALDH2*2 exhibitedstrong alcohol hypersensitivity caused by persistent accu-
mulation of a large amount of acetaldehyde. In Taiwanese
aborigines, the genotypes (ADH2, ADH3, and ALDH2)
controlling alcohol metabolism did not account for intra-
group (Atayal, Ami, Bunun, and Paiwan) differences in
vulnerability to alcoholism, except in the case of ADH2 for
the Ami ethnic group.24 Our study had numerous limita-
tions. First, it was a retrospective cohort study and
included only a small sample of aboriginal patients. Second,
tests for IL-28B genotype are not currently covered by the
Taiwanese National Health Insurance.
In conclusion, this study showed that naı¨ve HCV patients
with hazardous alcohol consumption can be treated with
peg-INF and ribavirin, and their SVR was similar to that of
nondrinkers. Furthermore, the completed treatment SVR
rate between patients with HCV genotype 1 and non-
genotype 1 infections was significantly different in the
nonaboriginal group but not in the aboriginal group.Acknowledgments
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